Ensysce Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ensysce Biosciences (ENSC).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingOverweight# Analysts1Avg. Consensus PT$2Upside to Avg. PT+316.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 20, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Initiate	Overweight	$2

Analyst Ratings News

PRO
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.

Benzinga Newsdesk

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $8.25 Price Valuation

Benzinga Newsdesk

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45/Share Price Valuation

https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05182026_ENSC_Sorensen.pdf

Benzinga Newsdesk

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation, Says "Earnings Release Show Positive Momentum"

https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03312026_ENSC_Sorensen.pdf

Benzinga Newsdesk

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_12092025_ENSC_Sorensen.pdf

Benzinga Newsdesk

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_11172025_ENSC_Sorensen.pdf

Benzinga Newsdesk

Ensysce Biosciences Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Ensysce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $8.25 Price Valuation

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45/Share Price Valuation

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation, Says "Earnings Release Show Positive Momentum"

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation

People Also Watch

People Also Watch

Ensysce Biosciences Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Ensysce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2

PROWatching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $8.25 Price Valuation

PROWatching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45/Share Price Valuation

PROWatching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation, Says "Earnings Release Show Positive Momentum"

PROWatching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation

PROWatching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $8.25 Price Valuation

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45/Share Price Valuation

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation, Says "Earnings Release Show Positive Momentum"

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation

PRO
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation